Fred Aslan Sells 25,500 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Key Points

• Artiva Biotherapeutics CEO Fred Aslan sold 25,500 shares of the company's stock for $69,615, reducing his position by 6.19% to 386,693 shares.
• The company's stock price increased by 12.7% recently, reaching $3.10, while the stock has fluctuated between a low of $1.47 and a high of $17.31 over the past twelve months.
• Artiva Biotherapeutics reported a quarterly loss of ($0.87) earnings per share, missing estimates, and analysts project a loss of -4.95 EPS for the current year.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 25,500 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $2.73, for a total value of $69,615.00. Following the completion of the transaction, the chief executive officer owned 386,693 shares of the company's stock, valued at approximately $1,055,671.89. This represents a 6.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Artiva Biotherapeutics Stock Up 4.0%

NASDAQ ARTV traded up $0.11 during trading hours on Friday, hitting $2.88. The company had a trading volume of 50,086 shares, compared to its average volume of 106,147. Artiva Biotherapeutics, Inc. has a 52 week low of $1.47 and a 52 week high of $17.31. The firm has a 50 day simple moving average of $2.34 and a 200 day simple moving average of $2.81.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.03). Research analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ARTV shares. Needham & Company LLC lowered their price target on Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, May 15th. HC Wainwright upgraded Artiva Biotherapeutics to a "buy" rating and set a $12.00 price target for the company in a research report on Wednesday, June 11th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $17.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of Artiva Biotherapeutics by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company's stock valued at $3,184,000 after buying an additional 6,828 shares during the period. Northern Trust Corp increased its stake in shares of Artiva Biotherapeutics by 3.8% during the fourth quarter. Northern Trust Corp now owns 117,112 shares of the company's stock valued at $1,180,000 after buying an additional 4,335 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Artiva Biotherapeutics by 26.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock valued at $165,000 after buying an additional 11,355 shares during the period. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $79,000. Finally, Nuveen LLC purchased a new stake in Artiva Biotherapeutics in the first quarter worth $144,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.